Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
7.67
-0.26 (-3.28%)
At close: Apr 28, 2026, 4:00 PM EDT
7.60
-0.07 (-0.91%)
After-hours: Apr 28, 2026, 6:56 PM EDT
Adicet Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
102
Market Cap
82.45M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 57.95M |
| Q32 Bio | 53.74M |
| Gossamer Bio | 48.47M |
| Sangamo Therapeutics | 39.55M |
| Pelthos Therapeutics | 16.80M |
| Alterity Therapeutics | 4.43M |
| Rani Therapeutics Holdings | 1.63M |
ACET News
- 6 weeks ago - Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - Business Wire
- 3 months ago - Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 3 months ago - Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones - Business Wire
- 4 months ago - Adicet Bio Announces Reverse Stock Split - Business Wire
- 5 months ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 months ago - Adicet Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Transcripts
- 6 months ago - Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 6 months ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire